CEFOVECIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C17H19N5O6S2
Molecular Weight	453.493
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CO\N=C(/C(=O)N[C@H]1[C@H]2SCC([C@@H]3CCCO3)=C(N2C1=O)C(O)=O)C4=CSC(N)=N4

InChI

InChIKey=ZJGQFXVQDVCVOK-QFKLAVHZSA-N

InChI=1S/C17H19N5O6S2/c1-27-21-10(8-6-30-17(18)19-8)13(23)20-11-14(24)22-12(16(25)26)7(5-29-15(11)22)9-3-2-4-28-9/h6,9,11,15H,2-5H2,1H3,(H2,18,19)(H,20,23)(H,25,26)/b21-10-/t9-,11+,15+/m0/s1

HIDE SMILES / InChI

Molecular Formula	C17H19N5O6S2
Molecular Weight	453.493
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	1
Optical Activity	UNSPECIFIED

Description
Sources: https://web.archive.org/web/20171115072542/https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm062340.pdf
Curator's Comment: description was created based on several sources, including: http://www.zora.uzh.ch/40272/4/Cefovecin.pdf | http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/veterinary/000098/WC500062064.pdf

Cefovecin is a third generation cephalosporin with a broad-spectrum of activity against Gram-positive and Gram-negative bacteria. Cefovecin differs from other cephalosporins in that it is highly protein bound and has a long duration of activity. As with all cephalosporins, the bactericidal action of cefovecin results from the inhibition of bacterial cell wall synthesis through binding to the penicillin-binding proteins (PBPs). It is indicated for the treatment of skin infections secondary superficial pyoderma, abscesses and wounds. Some gastrointestinal adverse effects like vomiting, anorexia or diarrhea were observed.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 234 Target ID: CHEMBL2354204 Sources: https://web.archive.org/web/20171115072542/https://www.fda.gov/downloads/AnimalVeterinary/Products/ApprovedAnimalDrugProducts/FOIADrugSummaries/ucm062340.pdf	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Secondary superficial pyoderma 2 Sources: https://www.zoetisus.com/products/dogs/convenia/documents/convenia_pi.pdf	Curative	Approved 8583	Convenia Approved Use CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis and skin infections (wounds and abscesses) in cats, caused by susceptible strains of Pasteurella multocida. Launch Date 2008
Wounds 16 Sources: https://www.zoetisus.com/products/dogs/convenia/documents/convenia_pi.pdf	Curative	Approved 8583	Convenia Approved Use CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis and skin infections (wounds and abscesses) in cats, caused by susceptible strains of Pasteurella multocida. Launch Date 2008
Abscesses 2 Sources: https://www.zoetisus.com/products/dogs/convenia/documents/convenia_pi.pdf	Curative	Approved 8583	Convenia Approved Use CONVENIA is indicated for the treatment of skin infections (secondary superficial pyoderma, abscesses, and wounds) in dogs caused by susceptible strains of Staphylococcus intermedius and Streptococcus canis and skin infections (wounds and abscesses) in cats, caused by susceptible strains of Pasteurella multocida. Launch Date 2008

PubMed

Title	Date	PubMed
Pharmacokinetics and pharmacodynamics of cefovecin in dogs.	2006-12	17083454
Pharmacokinetics of cefovecin in cats.	2006-12	17083455
Antimicrobial activity and spectrum of cefovecin, a new extended- spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America.	2006-07	16801403

Patents

Sample Use Guides

In Vivo Use Guide

A single injection of 8 mg/kg body weight. A second injection of 8 mg/kg may be administered if response to therapy is not complete.

Route of Administration: Other

In Vitro Use Guide

The minimum inhibitory concentrations (MICs) were determined for 45 clinical Pasteurella multocida isolates from infections in cats using applicable Clinical and Laboratory Standards Institute (CLSI) standards. The MIC90 for P. multocida was ≤ 0.06 ug/mL.

Substance Class	Chemical Created by `admin` on `Wed Apr 02 08:25:39 GMT 2025` Edited by `admin` on `Wed Apr 02 08:25:39 GMT 2025`
Record UNII	0D1OL46ZIE
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CEFOVECIN [MI]

Preferred Name

English

CEFOVECIN

Official Name

English

(6R,7R)-7-(((2Z)-2-(2-AMINO-1,3-THIAZOL-4-YL)-2-(METHOXYIMINO)ACETYL)AMINO)-8-OXO-3-((2S)-TETRAHYDROFURAN-2-YL)-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID

Systematic Name

English

CONVENIA

Brand Name

English

cefovecin [INN]

Common Name

English

5-THIA-1-AZABICYCLO(4.2.0)OCT-2-ENE-2-CARBOXYLIC ACID, 7-(((2Z)-2-(2-AMINO-4-THIAZOLYL)-2-(METHOXYIMINO)-1-OXOETHYL)AMINO)-8-OXO-3-((2S)-TETRAHYDRO-2-FURANYL)-, (6R,7R)-

Common Name

English

CEFOVECIN (EMA EPAR: VETERINARY)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C357